GlassScriptPhysician profile
Daniel Lawrence Jones
NPI 1447810841
$1,615.65
in general payments reported to CMS, 2019-2025
13 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.68 · 2020: $99.99 · 2023: $55.65 · 2024: $447 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.81 | 2023-2025 | |
| Oyster Point Pharma, INC. | $190.97 | 2024-2025 | Tyrvaya |
| Allergan, INC. | $99.99 | 2020 | |
| Alcon Vision LLC | $73.55 | 2024-2025 | Eysuvis, Argos, Simbrinza |
| Apellis Pharmaceuticals, INC. | $62.56 | 2025 | Syfovre |
| Harrow Eye, LLC | $59.02 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $56.75 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $53.08 | 2025 | |
| Bausch & Lomb Americas INC. | $37.87 | 2025 | Vyzulta |
| Alimera Sciences, INC. | $22.78 | 2024 | Iluvien, Yutiq |
| Johnson & Johnson Surgical Vision, INC. | $17.95 | 2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Amgen INC. | $16.64 | 2025 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.